GNETTI, Letizia
 Distribuzione geografica
Continente #
NA - Nord America 5.479
AS - Asia 4.325
EU - Europa 2.936
SA - Sud America 636
AF - Africa 276
Continente sconosciuto - Info sul continente non disponibili 196
OC - Oceania 3
Totale 13.851
Nazione #
US - Stati Uniti d'America 5.322
SG - Singapore 1.504
CN - Cina 1.070
IT - Italia 826
VN - Vietnam 708
BR - Brasile 462
IE - Irlanda 438
SE - Svezia 411
HK - Hong Kong 314
DE - Germania 246
BD - Bangladesh 239
FR - Francia 224
ZA - Sudafrica 173
NL - Olanda 123
GB - Regno Unito 115
IN - India 108
AT - Austria 102
RU - Federazione Russa 102
FI - Finlandia 96
CA - Canada 84
TR - Turchia 73
AR - Argentina 68
UA - Ucraina 51
BE - Belgio 45
IQ - Iraq 45
MX - Messico 38
CI - Costa d'Avorio 36
EC - Ecuador 34
JP - Giappone 34
CZ - Repubblica Ceca 31
ID - Indonesia 31
ES - Italia 30
KR - Corea 30
PL - Polonia 30
CO - Colombia 25
PK - Pakistan 23
PH - Filippine 19
UZ - Uzbekistan 16
MA - Marocco 13
CL - Cile 12
LT - Lituania 12
SA - Arabia Saudita 12
VE - Venezuela 12
GR - Grecia 11
IL - Israele 11
KE - Kenya 11
TH - Thailandia 11
EG - Egitto 10
TW - Taiwan 10
KZ - Kazakistan 9
PY - Paraguay 8
TN - Tunisia 8
CH - Svizzera 7
JO - Giordania 7
MY - Malesia 7
AZ - Azerbaigian 6
ET - Etiopia 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
CR - Costa Rica 5
HN - Honduras 5
JM - Giamaica 5
AL - Albania 4
AM - Armenia 4
BY - Bielorussia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
PS - Palestinian Territory 4
PT - Portogallo 4
SV - El Salvador 4
CG - Congo 3
GT - Guatemala 3
GY - Guiana 3
HU - Ungheria 3
IR - Iran 3
NG - Nigeria 3
OM - Oman 3
PR - Porto Rico 3
RO - Romania 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
RS - Serbia 2
SC - Seychelles 2
BB - Barbados 1
EU - Europa 1
Totale 13.643
Città #
Singapore 836
Ashburn 782
Chandler 552
San Jose 471
Dallas 461
Dublin 434
Santa Clara 328
Hong Kong 299
Beijing 243
Ho Chi Minh City 211
New York 197
Council Bluffs 186
Parma 183
Hanoi 179
Boardman 174
Johannesburg 162
Ann Arbor 160
Los Angeles 149
Shanghai 121
Munich 94
Lauterbourg 91
Dearborn 89
Hefei 87
Vienna 86
Chicago 73
Nanjing 69
Princeton 65
Milan 62
Izmir 44
Moscow 44
Buffalo 41
São Paulo 41
Rio Saliceto 40
Helsinki 39
Jacksonville 39
Bologna 38
Brussels 38
Wilmington 36
Abidjan 35
Jinan 34
Bremen 32
Columbus 32
Haiphong 32
Seattle 32
The Dalles 32
Da Nang 31
Frankfurt am Main 29
Montreal 27
Rome 27
Seoul 27
Marseille 24
Modena 24
Tokyo 24
Chennai 23
Nuremberg 23
Toronto 23
Warsaw 23
Atlanta 22
Des Moines 22
London 22
Tianjin 22
Denver 20
Guangzhou 20
Houston 20
Hebei 18
Kunming 18
Orem 18
Turku 18
San Mateo 17
Changsha 16
Curitiba 16
Jakarta 16
Phoenix 16
West Jordan 16
Fremont 15
Shenyang 15
Bengaluru 14
Boston 14
Naples 14
Rio de Janeiro 14
Tashkent 14
Brno 13
Brooklyn 13
Reggio Emilia 13
San Francisco 13
Stockholm 13
Baghdad 12
Belo Horizonte 12
Brescia 12
Hải Dương 12
Poplar 12
Quito 12
Redondo Beach 12
Amsterdam 11
Erbil 11
Jiaxing 11
Lahore 11
Mexico City 11
Nairobi 11
Redwood City 11
Totale 8.421
Nome #
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 254
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 215
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 210
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 208
227P Sexual dimorphism in immune profile of early and advanced NSCLC 204
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer 203
Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? 199
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 197
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 196
Solid-phase microextraction coupled to gas chromatography mass spectrometry followed by multivariate data analysis for the identification of volatile organic compounds as possible biomarkers in lung cancer tissues 194
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 193
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 185
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 183
Leiomioma metastatizzante benigno gigante 182
Pili canaliculi: a familial study 181
Early fetal akinesia sequence: A case report with unusual autoptic features 180
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 179
Human Papilloma Virus (HPV) status, P16INK4a and p53 overexpression in epithelial malignant and borderline ovarian neoplasms 177
Pulmonary metastasectomy for colorectal cancer: Analysis of prognostic factors affecting survival 176
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 175
A pulmonary infection by Actinomyces odontolyticus and Veillonella atypica in an immunocompetent patient with dental caries 173
Pleural tuberculosis: medical thoracoscopy greatly increases the diagnostic accuracy 172
Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features and emphasis in the HPV status 171
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 170
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 168
Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against “SARS-CoV-2 Nephropathy 167
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 167
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 166
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 166
Computed tomography - histology correlations of unusual lung tumors 165
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 164
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 164
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 163
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 160
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 159
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 157
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 157
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 155
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 155
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 154
KRAS: A Druggable Target in Colon Cancer Patients 153
A case of Solitary fibrous pleura tumor associated with severe hypoglycemia: the Doege-Potter 's Syndrome 150
Multiple primary malignancies involving lung cancer: a single-center experience 150
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 148
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 147
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 144
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 143
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 143
Onset of ANCA-positive EGPA with bilateral pleural effusion: a case report 141
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 139
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study 139
Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis 137
EXCEPTIONAL EVOLUTION OF BENIGN METASTASIZING LEIOMYOMAS OF THE LUNG 137
Giant intercostal nerve schwannoma in a patient with neurofibromatosis type 2 134
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 133
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer 133
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 132
CD26 is differentially expressed throughout the life cycle of infantile hemangiomas and characterizes the proliferative phase 131
Primary atypical carcinoid tumor of the mediastinum: A very rare finding 130
METACHRONOUS AND SYNCHRONOUS OCCURRENCE OF PRIMARY MALIGNANCIES IN PATIENTS WITH RESECTED NON SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE OBSERVATIONAL STUDY 130
TUMOR-INFILTRATING LYMPHOCYTES, PDL-1, BAP-1, VEGFR-2 AND IGF-1R EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA 128
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 128
Vulvar acantholytic squamous carcinoma: a case report with immunohistochemical and molecular study. 125
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 124
Tubercolosi pleurica multi-resistente in gravidanza: Challenge diagnostico e terapeutico 123
GIANT PRIMARY DEDIFFERENTIATED LIPOSARCOMA OF THE ANTERIOR MEDIASTINUM: AN EXTREMELY RARE OCCURRENCE 123
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 123
Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women 119
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 118
Oncocytic mucoepidermoid carcinoma of a submandibular gland: a case report and review of the literature. 117
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 116
Cryptogenic Fibrosing Pleuritis 115
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 114
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 114
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 113
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 111
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 109
Lung Manifestation of IgG4-related Disease. A multifaceted disorder. Presentation of two cases and short review of literature 108
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 106
Spread through air spaces in lung adenocarcinoma: Is radiology reliable yet? 103
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report 102
Very late recurrence of an apparently benign pheochromocytoma 100
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 99
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 97
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 96
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 95
Impact of preoperative chemoradiotherapy on tumor infiltrating lymphocytes in locally advanced rectal cancer: The SMART-STAR study 95
Malignant deciduoid pleural mesothelioma: A case report 95
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 94
Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database 92
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study 91
SOLITARY FIBROUS TUMOR OF THE PLEURA ASSOCIATED WITH SEVERE HYPOGLICEMIA: THE DOEGE-POTTER SYNDROME 86
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 84
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 72
Plasma exchange-sensitive syncytial glomerulopathy in a kidney transplant patient 71
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 67
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 62
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 58
Totale 13.851
Categoria #
all - tutte 49.331
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.331


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022381 0 13 5 18 8 13 76 27 20 31 25 145
2022/20231.828 168 240 106 151 151 222 24 125 522 14 76 29
2023/2024841 32 68 14 31 48 176 82 51 50 74 66 149
2024/20252.551 97 124 177 170 271 254 154 125 239 252 223 465
2025/20266.495 555 502 876 688 829 397 592 244 776 440 399 197
2026/2027303 129 174 0 0 0 0 0 0 0 0 0 0
Totale 13.851